Trial reportSignal transduction and targeted therapy2025
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2).
Trial report in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase Ib Study of Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Multicenter Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophageus
Neoadjuvant Short-Course Radiotherapy Followed by Tislelizumab Combined With Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: A Prospective, Multicenter, Exploratory Study
Who cites it
11 citing papers in PubMed.
- Concurrent versus sequential immune checkpoint inhibition in the neoadjuvant treatment of resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis.Clinical and translational radiation oncology · 2027Review
- Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradioimmunotherapy for locally advanced esophageal squamous cell carcinoma.International journal of clinical oncology · 2026Article
- Nanomaterial-driven spatiotemporal autophagy modulation: The dual-edged sword in precision cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Heterogeneity of adjuvant therapy effectiveness across post-neoadjuvant pathologic strata in esophageal squamous cell carcinoma: a retrospective cohort study.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Esophageal cancer recurrence after multimodality therapy: analysis of patterns and implications on long-term survival.Journal of thoracic disease · 2026Article
- [Clinical strategies for perioperative management of esophageal squamous cell carcinoma in the immunotherapy era].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Review
- Clinical-Radiomics Signature Predicts Pathologic Complete Response After Neoadjuvant Therapy in Oesophageal Squamous Cell Carcinoma.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- A squamous epithelial gene interaction perturbation network index for risk stratification in esophageal squamous cell carcinoma.Journal of Cancer · 2026Article
- Radiotherapy for overcoming immune checkpoint inhibitor resistance in esophageal squamous cell carcinoma.Frontiers in immunology · 2026Review
- Analyses on patterns of lymph node metastasis and its impact on prognosis in thoracic esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy versus chemotherapy alone: a single-center, retrospective cohort study.Frontiers in immunology · 2026Article
- Immunosuppressive tumor microenvironment and immunotherapy resistance of esophageal carcinoma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
The role of preoperative anti-PD-1 antibody (pembrolizumab) plus chemoradiotherapy (PPCT) in locally advanced, resectable esophageal squamous cell carcinoma (ESCC) is still unclear. We aimed to investigate the therapeutic effect and safety of PPCT followed by surgery in this study (NCT03792347, NCT04435197). Patients with histologically confirmed, locally advanced, and surgically resectable ESCC were enrolled. They received PPCT with paclitaxel/carboplatin or nab-paclitaxel/carboplatin, followed by esophagectomy 4-6 weeks after treatment. The primary endpoint was the pathologic complete response (pCR) rate. Tumor specimens, blood samples and subcutaneous tumor mouse models were utilized to explore and validate the dynamic characteristics of the tumor microenvironment (TME) of ESCC after PPCT. Among the 143 patients enrolled, 140 received neoadjuvant treatment, and 125 underwent surgery. The pCR rate reached 43.2% (54/125). During neoadjuvant period, 75.7% (106/140) of patients experienced grade three or higher-grade adverse events. After a median follow-up of 17.4 months, patients showed a one-year disease-free survival rate of 91.1%, and an overall survival rate of 96.5%. Using scRNA-seq and cytokine profiling, we identified high IL-6 levels as a predictor of response to PPCT. In vivo experiment revealed that IL-6 neutralization enhanced the efficacy of immunotherapy by increasing CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.